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ABSTRACT
Dendritic cells (DCs) are specialized, bone marrow–derived leukocytes critical to the onset of both innate and
adaptive immunity. The divisions of labor among distinct human DC subtypes achieve the most effective
balance between steady-state tolerance and the induction of innate and adaptive immunity against pathogens,
tumors, and other insults. Maintenance of tolerance in the steady state is an active process involving resting or
semimature DCs. Breakdowns in this homeostasis can result in autoimmunity. Perturbation of the steady state
should first lead to the onset of innate immunity mediated by rapid responders in the form of plasmacytoid and
monocyte-derived DC stimulators and natural killer (NK) and NK T-cell responders. These innate effectors
then provide additional inflammatory cytokines, including interferon-, which support the activation and
maturation of resident and circulating populations of DCs. These are critical to the onset and expansion of
adaptive immunity, including Th1, Th2, and cytotoxic T-lymphocyte responses. Rodent models are now
revealing important data about distinct DC precursors, homeostasis of tissue-resident DCs, and DC turnover
in response to inflammation and pathological conditions like graft-versus-host disease. The use of defined DC
subtypes to stimulate both innate and adaptive immunity, either in combination or in a prime-boost vaccine
sequence, may prove most useful clinically by harnessing both effector cell compartments.
© 2007 American Society for Blood and Marrow Transplantation
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uman Dendritic Cells: Distinct Subsets and
ematopoietic Precursors
From the initial description of dendritic cells
DCs) in human skin [1] to the discovery of DCs in
ouse spleen almost a century later [2], progress in
he study of DC biology exploded in the 1990s. In-
estigators developed cytokine-driven methods for ex-
anding and differentiating DCs ex vivo in both
ouse and human systems, and further reﬁnements
ontinue to emerge. For the ﬁrst time, sufﬁcient num-
ers of DCs have become accessible for large-scale
tudy and applications.
DCs are a central player in all immune responses,
oth innate and adaptive. DCs are exceptionally po-
ent immunogens under inﬂammatory conditions, yet
re also critical to the induction and maintenance of melf-tolerance in the steady state. The heterogeneity of
Cs and their activation states afford investigators
ore opportunities to deﬁne and manipulate the im-
une response using these specialized leukocytes.
Human DCs are all bone marrow–derived leuko-
ytes and compose at least 4 types deﬁned under
ytokine-driven conditions in vitro (Figure 1). In
ddition, trace populations of DCs also circulate in
uman blood. One type shares phenotypic (lineage
egative, CD11c, CD86, CD123/low, and HLA-
Rbright) features with cytokine-generated myeloid
r conventional DCs in vitro. The other circulating
Cs, termed plasmacytoid because of their mor-
hological resemblance to plasma cells [3], are also
ineage-negative, CD86, BDCA-2, and HLA-
Rbright, but CD11cneg and CD123bright. Freshly iso-
ated plasmacytoid DCs express much lower levels of
ajor histocompatibility complex (MHC) and co-
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J. W. Young et al.24timulatory molecules than their conventional DC
ounterparts [3]. They also capture, process, and load
ntigens onto MHC molecules less effectively. Thus,
hese nonactivated plasmacytoid DCs are poor stim-
lators of T lymphocytes. Interleukin (IL)-3, in com-
ination with CD40L or microbial products, leads to
ull plasmacytoid DC activation, abundant secretion
f type I interferons (IFN), and more potent lympho-
yte stimulation [4-6]. CD83 is the cardinal hallmark
f both plasmacytoid and conventional or myeloid DC
aturation in both mice and humans [7].
A potential point of confusion is that all murine
Cs, be they myeloid or plasmacytoid, express
D11c, with the exception that CD11cneg/low Lang-
rhans cells (LCs) up-regulate CD11c only with mat-
ration. Along with low levels of CD11c, murine plas-
acytoid DCs also express B220 and Gr1 and
p-regulate CD123 only after Flt3-L treatment [8,9].
Monocyte-derived DCs (moDCs) and plasmacy-
oid DCs have been labeled DC1 and DC2, respec-
ively, because of their propensity to stimulate Th1
ersus Th2 type responses, with plasmacytoid DCs
mplicated as being somehow tolerogenic. This over-
impliﬁcation, however, neglects stimulation of more
aried T-cell responses, including the major physio-
ogical role of plasmacytoid DCs as the most abundant
ource of type I IFNs after activation by viruses [4-6].
t also overlooks the fact that both types of DCs can
timulate the expansion of regulatory or suppressor T
igure 1.Development of human DC subsets. Precursors in blood a
xist in vivo for each DC type generated with cytokines in vitro,
opulations of circulating myeloid or conventional DCs and plasm
omplex processes but are necessary for DCs to exert optimal im
timulating factor; KL, c-kit-ligand. (Reprinted from The Journal o
005 The American Association of Immunologists, Inc.)ells [10-13], with immature or semimature forms Iunctioning in the steady state to maintain peripheral
olerance and mature forms probably using this mech-
nism to turn off otherwise unchecked immune re-
ponses. Designations like DC1 and DC2 are best
voided in favor of using the more speciﬁc terms for
arious DCs.
C Maturation and Migration to Secondary
ymphoid Organs
Manipulation of immunity using DCs generated
n vitro should exploit the less mature and nonacti-
ated forms to promote tolerance and the activated
nd mature forms to break tolerance and promote
mmunity. That said, under physiologic steady-state
onditions, DCs are a major component of lymphoid
issues. In this setting, DCs are mostly immature or
emimature and efﬁciently process self-antigens to
nduce and maintain tolerance [14-16]. All DCs re-
uire some form of terminal maturation to become
ully immunogenic, however. Thus, DC maturation is
pivotal event in the control of innate and adaptive
mmunity. Microbial products constitute a physiologic
ctivation stimulus via Toll-like receptors (TLRs) on
oth plasmacytoid and conventional DCs. CD40L
CD154), either expressed by activated T cells or as a
ultimeric recombinant protein, can also mature
Cs. A combination of inﬂammatory cytokines that
ncludes IL-1-, tumor necrosis factor (TNF)-,
e marrow (left section) can give rise to 4 types of DCs. Counterparts
gh the moDC has proven more elusive to identify in situ. Trace
DCs also exist in blood. Terminal maturation and activation are
enicity. FL, Flt-3 ligand; GM, granulocyte macrophage colony-
nology 2005;175:1373-1381 and used with permission, Copyrightnd bon
althou
acytoid
munog
f ImmuL-6, and prostaglandin E2 [17] is often used to ma-
t
t
A
D
a
o
h
a
a
p
h
t
h
h
m
p
T
m
t
t
c
t
a
t
t
T
i
i
t
T
L
a
o
e
a
o
b
T
C
a
o
r
r
T
m
i
u
c
a
b
a
T
e
w
s
s
e
t
F
a
t
c
s
o
t
A
Dendritic Cells in Transplantation and Immune-Based Therapies 25ure DCs for study in vitro and use in clinical vaccine
rials.
ntigen Uptake, Processing, and Presentation:
Cs as Cross-Presenters
DCs share most features of antigen-processing
nd class I and II MHC-restricted presentation with
ther antigen-presenting cells. DCs are endowed,
owever, with the capacity to cross-present exogenous
ntigens on the DCs’ own class I MHC molecules to
utologous T cells regardless of the MHC alleles ex-
ressed by the antigen source [18-20]. Investigators
ave emphasized moDCs in studies of cross-presen-
ation because of their ready availability in vitro and
igh phagocytic activity. Cytokine-induced, CD34
ematopoietic progenitor cell(s)-derived LCs are
uch less phagocytic than moDCs, yet elicit more
otent T-cell responses by cross-presentation [21].
herefore, much more Ag phagocytosed by moDCs
ust undergo sequestration and degradation, rather
han processing for MHC-restricted presentation.
Much has also been made of the distinction be-
ween apoptotic and necrotic cell death as a source of
ross-presented antigen. Whether antigen remains in-
act or denatured during apoptosis or necrosis, as well
s any association with additional danger signals, are
he greater determinants of effective cross-presenta-
ion and a tolerant or immune outcome [22].
he Roles of TLRs and C-Type Lectin Receptors
n DC-Based Immunity
DCs express pattern recognition receptors, which
igure 2. Inﬂammatory perturbations of the steady state lead to DC
re the principal cellular components of innate immunity as they pe
he right are the principal cellular components of acquired or a
onditions, antigens capture segregates to immature DCs (shown at
timulation being an acquired property of mature DCs (shown at bo
f inﬂammation, where most DCs in lymphoid organs are immature
olerance. (Reprinted from The Journal of Immunology 2005;175
ssociation of Immunologists.)nclude TLRs. TLR–ligand interactions include pep- midoglycan binding of TLR2, viral dsRNA binding of
LR3 [mimicked by synthetic dsRNA, eg, poly(I:C)],
PS binding of TLR4, viral ssRNA binding of TLR7,
nd unmethylated bacterial CpG DNA motif binding
f TLR9. Conventional or myeloid DCs express sev-
ral of TLR1–6 and 8, depending on the subset and
ctivation state [23,24]. Plasmacytoid DCs are the
nly human DCs that express TLR7 and 9, although
lood monocytes express TLR7 and B cells express
LR9 [23,24]. Ligand binding of TLRs up-regulates
D83, cytokine secretion, costimulatory molecules,
nd CCR7, which drives DC migration to T-cell areas
f draining lymph nodes.
These early-activated DCs thus play an important
ole in the bystander activation of other DCs and the
ecruitment of natural killer (NK), NKT, and CD8
cells, which then secrete IFN- and other inﬂam-
atory cytokines that support the ensuing adaptive
mmune response (Figure 2). Thus, appropriate stim-
lation of TLRs on DCs by their respective ligands
an initiate the entire spectrum of innate and, in turn,
cquired immunity. The inﬂammatory cytokine com-
ination used in vitro for terminal DC maturation and
ctivation [17] mimics the sequelae of physiological
LR–ligand binding.
Another group of pattern recognition receptors
xpressed by DCs are the C-type lectin receptors,
hich bind the carbohydrate moieties of glycoprotein
elf-antigens and pathogens for processing and pre-
entation on MHC molecules. Resident, resting DCs
xpress these receptors, which are specialized for an-
igen capture and processing. Expression by immature
lation of innate and adaptive immune responses. Shown on the left
the currently understood role of human dendritic cells. Shown on
immunity as they pertain to human DCs. Under inﬂammatory
the right), with antigen-presentation and immunogenic lymphocyte
n the right). Not shown is the steady-state condition in the absence
imature and process and present self-antigens to induce or maintain
1381, and used with permission, Copyright 2005 The Americanstimu
rtain to
daptive
top on
ttom o
or sem
:1373-oDCs includes among others, the macrophage man-
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J. W. Young et al.26ose receptor (MMR; CD206), DEC-205 (CD205),
C-SIGN (CD209), low levels of BDCA-2, and Dec-
in-1. LCs also express Langerin (CD207) [25] and
ow levels of DEC-205 (CD205). Dermal-interstitial
endritic cells (DDC-IDCs) express DEC-205 and
C-SIGN [26]. As DC function changes with matu-
ation from antigen uptake to antigen presentation,
he expression of C-type lectin receptors diminishes,
ith the exception of DEC-205, which increases with
C activation [26,27].
DCs use C-type lectin receptors to sample and
resent self and harmless environmental antigens in
he steady state and thereby maintain peripheral tol-
rance. Simultaneous exposure to an activating stim-
lus like TLR-binding ligands or CD40L can override
ny tolerizing function of C-type lectin receptors and
ead to immune activation [27,28].
c- Receptors for Uptake of Immune Complexes
r Opsonized Antigen by DCs
Resident populations of mouse and human DCs
nd their precursors express some combination of ac-
ivating (CD16 [mouse; human monocyte precursor
ubset], CD32a [human only], and CD64 [mouse and
uman]) and inhibitory (CD32b [mouse and human])
c- receptors [29]. Among cultured and cytokine-
nduced human DCs, only circulating blood DCs and
oDCs maintain expression of Fc- receptors [30].
hese are not passive uptake receptors but; signal the
ell using ITIM and ITAM motifs [29]. The balance
f activating and inhibitory Fc- receptors; the bind-
ng avidity of allelic receptor isoforms; the species,
ubclass, and density of the opsonizing IgG antibody;
nd the size of the immune complex all determine the
utcome of these receptor–ligand interactions [30].
argeting tumor antigens to Fc gamma receptors on
Cs increases the efﬁciency of antigen cross-presen-
ation [31,32]. Activating Fc gamma receptors also
romote DC maturation and activation [30]. Greater
elative expression and ligation of CD32b are sufﬁ-
ient to counter DC maturation and activation in-
uced by positive signaling through CD32a [30].
D34 HPC-Derived LCs Are Superior
timulators of Class I MHC-Restricted
ytotoxic T Lymphocytes In Vitro
Direct comparisons of cytokine-generated moDCs,
Cs, and DDC-IDCs in vitro have shown that all
xpress comparable maturation phenotypes and stim-
latory function in allogeneic mixed leukocyte reac-
ions. However, LCs are superior stimulators of cyto-
oxic T lymphocytes (CTLs), at least against a recall
iral antigen and cross-presented tumor antigen [21],
hich supports the hypothetical advantage of using
D34-derived DCs that include LCs as tumor vac-
ines [33]. LCs are potent stimulators of CTLs in the iomplete absence of bioactive IL-12p70 [21]. This is
ot an artifact of their culture in vitro, because mature
C and DDC emigres from human skin also do not
ecrete IL-12p70 [34]. IL-12 is supposedly essential
or generating Th1 and CTL responses, but perhaps it
as been overemphasized due to inadvertent measure-
ent of inactive IL-12p40 homodimers [35]. IL-
2p70 supports stimulation of Th1 and CTLs, but
robably only by ﬁrst stimulating NK cells to secrete
FN-, which conditions DCs and Th1 responses
36,37].
oDCs Are Superior Stimulators of NK
nd NKT Cells In Vitro
Human moDCs are the most potent myeloid DCs
or stimulating NK cell proliferation and cytotoxicity
38]. LCs lack sufﬁcient IL-12p70 secretion to induce
K cell activation but provide unidentiﬁed factors
hat sustain NK cell proliferation and survival after
ctivation by moDCs [38].
NKT cells constitute a trace population of T cells
hat express an invariant T-cell receptor (TCR)-
hain and otherwise share some features of NK cells.
n response to self-glycolipid antigens presented on
D1d, NKT cells exert suppressor functions through
L-4 [39]. Tumors like melanoma provide glycolipid
igands like GD3 [40], and the drug alpha-galactosyl-
eramide (alpha-GalCer) is an artiﬁcial ligand. The
resentation of glycolipid ligand by CD1d-expressing
Cs [41-43], however, or the simultaneous delivery of
microbial stimulus to DCs resulting in high IL-
2p70 secretion [44], leads to robust activation of
KT cells and IFN- secretion. The critical operative
actor is the need for DCs to convert NKT cells from
uppressor to effector function. Among conventional
Cs, only moDCs and DDC-IDCs express CD1d,
nd only moDCs secrete IL-12p70 [21], so only
oDCs should mediate NKT-cell activation.
In either setting, both DC-stimulated NK and
KT cell innate immune effectors become potent
ources of IFN- and other inﬂammatory cytokines.
his can support the innate maturation of resident
opulations of DCs through a reciprocal activating
nteraction that expands the ensuing adaptive Th1
esponse mediated by cytotoxic effectors (Figure 2).
HE ROLE OF DCs IN MOUSE MODELS OF
RAFT-VERSUS-HOST DISEASE
Mouse models have proven critical to the study of
llogeneic hematopoietic stem cell transplantation be-
ause of the wide variety of available strains with
ell-deﬁned genetic disparities. Mice also accept mis-
atched transplants after a single dose of total body
rradiation and in the absence of posttransplantation
mmunosuppression. This is due to less minor anti-
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Dendritic Cells in Transplantation and Immune-Based Therapies 27enic diversity, more controlled environmental expo-
ure to infection, and decreased contamination by
lood T cells compared with humans. Nevertheless,
raft-versus-host disease (GVHD) does occur in mice
ndergoing allogeneic bone marrow transplantation;
nd the preparative regimen, degree of MHC match-
ng, and cell dose all inﬂuence GVHD in mice as in
umans.
ntigen-Presentation to T Cells and GVHD
Although it now seems intuitive that mature T
ells in the donor allograft mediate GVHD, this was
ot proven until the late 1970s by Korngold and
prent [45], who also demonstrated the need for an-
igen processing and presentation of host antigens to
onor T cells [46]. DCs are professional antigen-
resenting cells (APCs) that are central to the initia-
ion of T-cell responses to both MHC and minor
istocompatibility antigens (miHAs) through two dis-
inct pathways. Ligation of the donor TCR by MHC
olecules on recipient DCs represents a direct path-
ay. Polymorphic residues in the MHC binding
roove, which themselves are not accessible to TCRs,
ffect binding of peptides that are recognized by allo-
eneic T cells. This magniﬁes the antigenic effect of
HC polymorphisms and accounts for the much
igher frequency of T cells (1%–10%) reactive with
llogeneic MHC compared with those that react with
iHAs presented by MHC-identical individuals [47].
onor T cells use an indirect pathway to recognize
iHAs, which are peptides derived from polymorphic
enes unique to the host but recognized because they
re presented by shared MHCmolecules in the setting
f matched allotransplants [48]. The holy grail in
linical transplantation, often studied in mouse mod-
ls, is to stimulate T cells against miHAs unique to a
alignancy that are not shared by normal tissues, thus
chieving graft-versus-tumor (GVT) activity without
VHD.
nfluence of DC Turnover on GVHD
DCs are radioresistant and hence can survive this
nd many other pretransplant conditioning modalities
hat target cycling or proliferating cells. Persistent
ost DCs can function as initiators, as well as targets
f GVHD reactivity against either minor or major
istoincompatibilities [49,50]. Both residual host and
ngrafting donor APCs contribute to maximal GVHD
eactions [51], however, the latter by cross-presenta-
ion of host antigens to engrafting donor T cells.
hus, mechanisms regulating DC homeostasis after
ransplantation inﬂuence GVHD outcome.
The prevailing view has been that DCs trafﬁc to
ymphoid organs, where their turnover is quite rapid,
nd that a continuous replenishment of precursors
olely from blood maintains DC homeostasis in the deriphery. Recent data from parabiotic mice that
hare a common circulation but separate organs have
hallenged this concept. An epidermal DC population
nown as LCs can self-renew in the skin of these
arabiotic mice from resident precursors and remain
f host origin for an extended period [52].
LCs and dermal DCs can also survive myeloabla-
ive conditioning by radiation and persist for many
onths after transplantation of puriﬁed stem cells
r T-cell–depleted bone marrow in the absence of
VHD ([53] and Bogunovic et al, in press, Journal of
xperimental Medicine). The presence or absence
f GVHD is critical. In the absence of GVHD, trace
opulations of low-level cycling precursors in the skin
re sufﬁcient to renew those LCs or dermal DCs that
rafﬁc to secondary lymphoid tissues, thus maintaining
heir host origin. In contrast, the insult of GVH re-
ctions against peripheral DCs exceeds the capacity of
ocal precursors to replenish these host populations, so
hat circulating donor marrow-derived DC precursors
ll the resulting void.
Depletion of radioresistant LCs and replacement
y donor DCs prevent cutaneous GVHD in MHC-
ismatched allotransplants [53]. Furthermore, alloge-
eic T cells left in donor marrow, once primed against
ost miHA or MHC, eliminate host DCs from
VHD target organs. These are then replaced by
onor marrow-derived DCs [53]. Previous acute cu-
aneous GVHD in humans also correlates with com-
lete donor LC chimerism, again supporting a role of
llogeneic T cells in promoting donor LC engraft-
ent [54].
All of these data show that mechanisms regulating
C homeostasis offer potential targets for controlling
raft–host interactions. Studies have not yet formally
etermined whether one type of DC is more or less
esponsible for initiating or being targeted (or both)
y GVHD reactions. Mouse models of conditional
C ablation currently under study may resolve this
uestion.
UMAN DC BIOLOGY IN CLINICAL HEMATOPOIETIC
TEM CELL TRANSPLANTATION
Early studies invoking the concept of the immu-
ostimulatory passenger leukocyte in solid organ
ransplantation predicted that DCs play a central role
n clinical hematopoietic stem cell transplantation
HSCT), as both initiators and targets of graft–host
nteractions. DCs are terminally differentiated and
omprise long-lived resident populations of APCs in
he periphery. Like other nonproliferating cells, DCs
re resistant to myeloablative regimens that target
ycling cells, including total body irradiation. As in the
ice, persistent host DCs can present antigen by the
irect pathway; and engrafting donor DCs would use
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J. W. Young et al.28he indirect pathway to cross-present host antigens, in
oth cases to engrafting donor T cells. The cytokine
torm associated with pretransplantation conditioning
nd the early peritransplantation period can activate
Cs to present these antigens in an immunogenic
anner [55]. Investigators have not yet determined
ow to maintain DCs in an immature or semimature
tate to promote graft–host tolerance while promot-
ng the desired graft-versus-leukemia (GVL) or GVT
ffects exerted by the allotransplant.
C Chimerism after Allogeneic HSCT and GVHD
Because there is ongoing emigration of DCs from
he circulation, replenishment after allogeneic HSCT
epends on engraftment of donor HSCs and precur-
ors. Thus, DCs of both types decrease after condi-
ioning but recover promptly, lagging somewhat be-
ind monocytes. Most chimerism studies have focused
n conventional or myeloid DCs, ﬁnding a rapid con-
ersion to donor type even though small numbers of
ost DCs may persist for extended periods, especially
fter reduced-intensity conditioning [56]. Circulating
C counts also fall during clinically signiﬁcant acute
VHD, suggesting the effects of therapy (especially
teroids), more rapid turnover with migration into the
issues, or both [57].
Resident populations of DCs in peripheral tissue
ay be more relevant to acute GVHD; these have
een addressed in mouse studies discussed above. Re-
ently, Collin et al [54] found that host epidermal LCs
eclined and then recovered with donor LCs more
apidly after myeloablative conditioning than with re-
uced-intensity conditioning, although the nadirs
ere comparable between days 14 and 21. Recovery to
retransplantation levels with donor LCs was more
apid in the absence of acute GVHD but more com-
lete in the presence of acute GVHD, suggesting a
ole for allogeneic T cells in promoting LC engraft-
ent as in the mice [52,53]. Dermal DC reconstitu-
ion can follow similarly rapid turnover by about day
100 [58], although some host dermal DCs remain,
specially after reduced-intensity conditioning (Bo-
unovic et al, submitted). Recent data indicate that an
ncreasing proportion of conventional or myeloid
D11c DCs that coexpress the activation marker
MRF-44 precedes the onset of clinically signiﬁcant
cute GVHD (Lau et al, in press, Transplantation).
onitoring of such subsets in the blood may have
redictive value.
Preventive and therapeutic immunosuppressive
gents also affect DC numbers. Alemtuzumab (Cam-
ath-1H) rapidly depletes circulating host DCs but
oes not alter donor DC engraftment [59]. In con-
rast, alemtuzumab does not affect other DCs, like
Cs or dermal DCs, which do not express the CD52
arget epitope [60,61]. Other antibodies directed Ggainst CD83 or CMRF-44 may merit clinical evalu-
tion given their effects in vitro [61] and in vivo.
yclosporin A and tacrolimus (FK506) can impair
ntigen processing by DCs [62] but, like steroids, are
onselective and also exert prominent effects on T
ells by calcineurin inhibition. Sirolimus (rapamycin),
hich blocks the signal transduction resulting from
igation of the IL-2, -4, and -6 receptors in T cells,
lso suppresses DC immunogenicity [63]. Thus, drugs
hat block DC function should modulate immune in-
eractions in allogeneic HSCT. More targeted re-
gents are still required, however, especially if the goal
s to maintain viral immunity and GVL effects while
liminating GVHD and avoiding overly broad im-
une suppression and its complications. Equal con-
ideration may be given to using recipient DCs in a
olerogenic form to pretreat donor stem cell sources
nd minimize allogeneic T-cell responses.
Cs and Stimulation of GVT Effects
GVHD and GVT/GVL are distinct but overlap-
ing syndromes. It is more difﬁcult to separate these
immunologic processes when the tumor burden is
igh, so that the “requirement” for GVHD to me-
iate GVT/GVL is a relative one. Patients in solid
emission who undergo transplantation because of
he high risk of relapse do not need to develop
VHD to attain a GVT/GVL beneﬁt [64]. In con-
rast, high tumor burdens are associated with unac-
eptably high rates of recurrence in the face of T-cell
epletion [65].
The contributions of DCs to the GVT/GVL ef-
ect merit critical examination. Host DCs presenting
eukemic antigens either directly or by cross-presen-
ation should stimulate at least part of the antileuke-
ic response. To the extent that distinct T cells may
ediate either GVH or GVT/GVL reactions, but not
oth [66], investigators are beginning to evaluate
hether DC subtypes separately dictate these re-
ponses at the level of antigen presentation [60]. In
act in the absence of concomitant tissue injury, per-
istent host LCs that migrate from skin to draining
ymph nodes can stimulate potent graft responses
gainst host antigens shared with lymphohematopoi-
tic elements, thus supporting GVT/GVL without
VHD in an MHC-matched mouse allogeneic bone
arrow transplantation model [67]. This is relevant
ot only to the immunologic effects mediated by the
llograft, but also to those exerted by donor leukocyte
nfusions to treat recurrent disease. Once again, the
oal is to target miHAs that are selectively expressed
y malignant cells and not shared with normal tissue,
hich would result in the overlapping development of
VHD [48].
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Dendritic Cells in Transplantation and Immune-Based Therapies 29utologous DC Immunotherapy
The development of methods for the large-scale
eneration of human DCs has facilitated their appli-
ation as active immunogens in vivo against tumor-
ssociated antigens. This allows coupling of tumor
ntigen with the myriad costimulatory, chemokine,
nd cytokine mediators provided by DCs, which, to-
ether with their migratory properties to draining
ymph nodes, leads to the stimulation of antitumor
ellular immunity. Because early trials have had to
emonstrate safety, most treated patients have had
dvanced disease. However, the greatest efﬁcacy of
C vaccines, like other cell therapies, is most likely in
inimal residual disease states where the tumor bur-
en is not so unbalanced against the immune re-
ponse. Host factors that disrupt normal DC biology
ould also be less dominant in the presence of mini-
al disease states.
DCs can be obtained from various sources, includ-
ng nondividing blood monocyte precursors or cycling
D34 progenitors in cord blood, granulocyte col-
ny-stimulating factor–elicited peripheral blood stem
ells, or bone marrow. All of these methods depend on
ecombinant cytokine support in vitro, and terminal
aturation is essential for optimal stimulation of T
ell immunity. In addition to cytokine-supported
ethods, preformed circulating DCs can also be iso-
ated from blood by density gradient [68,69] or direct
mmunoselection [70,71]. However, investigators are
ncreasingly recognizing that the DC progeny com-
rise a more heterogenous population than was pre-
iously understood, with attendant divisions of labor
or stimulating both innate and adaptive immunity
21,38].
Both the selection of the most effective DC sub-
ype for vaccination and the optimal approach for
ntigen loading pose additional challenges. The sim-
lest approach has been incubation with synthetic and
ometimes heteroclitic peptides with deﬁned HLA
estrictions, commonly melanosomal antigens re-
tricted to HLA-A*0201. Other approaches have used
umor lysates for uptake and cross-presentation
21,72,73]. Receptor targeting is also drawing increas-
ng attention [27]. Genetic modiﬁcation by DNA [74]
r RNA [75] transfection offers other potential advan-
ages because this can provide additional class I
HC–restricted antigens, as well as class II MHC–
estricted helper epitopes, together with more sus-
ained Ag expression.
Routes of immunization also vary, but a consensus
s developing on intradermal vaccination. This is dif-
cult to do reliably but seems more effective than
ubcutaneous vaccination, probably due to the rich
ymphatics at the epidermal–dermal junction. Intra-
enous administration does not compare favorably
ith the intradermal route in animal and limited clin- vcal comparisons. Intranodal vaccination, of course,
emoves considerable uncertainty but cannot be
idely applied. The optimum frequency and duration
or a DC therapeutic vaccination schedule remains an
ducated guess. There are clear examples, however, of
ate responses after several months; and there is an
volving view that maintaining an ongoing vaccination
chedule in a responding patients may be wise [73].
ortunately, it appears that all of the DC preparations
an be cryopreserved and thawed for injection, but
linical trials will need to establish whether the cost of
xtended maintenance schedules can be justiﬁed.
Early-phase trials depend heavily on proxy mea-
urements in vitro of responses to vaccines adminis-
ered in vivo. Clinical responses are of interest, but
emain mostly anecdotal in small numbers of patients
mong the great majority treated in the presence of
ubstantial systemic disease. These include antigen-
riven ELISpot assays for measurement of IFN-
ecretion, T-cell reactivity with tetramers/pentamers
onsisting of deﬁned peptide antigens with known
HC restrictions, intracellular cytokine secretion as-
ays, and occasionally CTL assays against radiolabeled
argets that correlate with clinical responses [76].
The literature is replete with early phase I and II
tudies of DC-based vaccines; a list of these is available
t http://www.mmri.mater.org.au. Although the ob-
ective observer may reasonably be disappointed by
he slow pace of progress to this point, one should
egin by discounting studies that used immature DCs
hat were not sufﬁciently immunogenic, routes and
chedules of immunization that were unlikely to suc-
eed, and patients with advanced disease in whom
here was inadequate time to respond. Having elimi-
ated such ﬂawed studies, there remain other trials,
specially in melanoma and lymphoma, where re-
ponses in vitro have been documented and clinical
esponses have emerged [33,69,73,77,78]. It is note-
orthy that the limited T-cell precursor frequency to
tumor-associated antigen may frustrate even the
ost effective DC vaccine preparation [79], and thus
he prospect of combining DC vaccination with si-
ultaneous passive T-cell administration is a consid-
ration.
Could this therapy be applied in allogeneic
SCT? Indeed, there are potential advantages in ex-
loiting a minimal residual disease state and the auto-
eactive potential of the recovering T-cell repertoire,
hich is relatively devoid of regulatory T cells. This is
n fact the basis for homeostatic proliferation of newly
ngrafting T cells that can be targeted toward speciﬁc
ntigens as they repopulate lymphoid niches unfet-
ered by T regs. Donors could also be vaccinated with
Cs and their recipients’ tumor associated antigen(s)
efore harvest and transplantation, as described for
yeloma idiotype. Similarly, the use of donor DCs to
accinate recipients of allogeneic HSCT with tumor-
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J. W. Young et al.30ssociated antigen(s) may boost immune response in
he form of more speciﬁc donor lymphocyte infusions
ith minimal risk of GVHD. The use of leukemic
Cs has also been suggested in this setting. Such
trategies to enhance GVT/GVL may prove useful if
nti-DC therapy is used to prevent GVHD. Other
evelopments, such as receptor targeting to DCs in
ivo with anti-CD205 or comparable reagents, may
ake DC immunotherapy even more applicable.
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